Post-earnings recap
Reported
Tue, Oct 28, 2025
EPS actual
$0.06
EPS est.
$-0.10
EPS surprise
+158.25%
1-day move
+27.04%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arcutis Biotherapeutics reported a strong earnings surprise with an EPS of $0.06, which significantly exceeded expectations. The stock reacted positively, rising by 27.04% as investors responded favorably to the unexpected profitability. However, the absence of revenue figures and future guidance leaves some uncertainty about the company's financial trajectory.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.06 | N/A | +158.25% |
| Revenue | N/A | N/A | N/A |
Management conveyed a positive outlook on the company's operational progress. They emphasized their commitment to innovation and growth.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They highlighted ongoing efforts in product development and market expansion.